156 related articles for article (PubMed ID: 36964333)
1. Prognostic impact of endoscopic response evaluation after neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a nationwide validation study.
Matsuda S; Kitagawa Y; Okui J; Okamura A; Kawakubo H; Takemura R; Kono K; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Esophagus; 2023 Jul; 20(3):455-464. PubMed ID: 36964333
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H
Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560
[TBL] [Abstract][Full Text] [Related]
4. A nationwide validation of the prognostic impact of pathological response and the distribution of recurrence patterns in responders after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Matsuda S; Kitagawa Y; Kawakubo H; Okui J; Okamura A; Takemura R; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Esophagus; 2023 Apr; 20(2):205-214. PubMed ID: 36319809
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor after Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Matsuda S; Kawakubo H; Tsuji T; Aoyama J; Hirata Y; Takemura R; Mayanagi S; Irino T; Fukuda K; Nakamura R; Takeuchi H; Kitagawa Y
Ann Surg Oncol; 2022 Apr; 29(4):2673-2680. PubMed ID: 34812985
[TBL] [Abstract][Full Text] [Related]
6. Nationwide Validation Study of the Prognostic Significance of Stratification Using Pathological Stage and Response to Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Matsuda S; Kitagawa Y; Okui J; Okamura A; Kawakubo H; Takemura R; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Ann Surg; 2023 Aug; 278(2):e234-e239. PubMed ID: 36538635
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Pre-treatment Circumferential Tumor Location in Patients With cStage IB-III Esophageal Squamous Cell Cancer.
Nagasawa S; Oshima T; Hara K; Nakazono M; Kumazu Y; Aoyama T; Yamada T; Ogata T; Rino Y; Saito A; Yokose T; Grabsch HI
Anticancer Res; 2023 Jun; 43(6):2697-2705. PubMed ID: 37247934
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Stratification Using Pathological Stage and Response to Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Matsuda S; Kawakubo H; Okamura A; Takahashi K; Toihata T; Takemura R; Mayanagi S; Takeuchi H; Watanabe M; Kitagawa Y
Ann Surg Oncol; 2021 Dec; 28(13):8438-8447. PubMed ID: 34142294
[TBL] [Abstract][Full Text] [Related]
11. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
12. Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A).
Nomura M; Kato K; Ando N; Ohtsu A; Muro K; Igaki H; Abe T; Takeuchi H; Daiko H; Gotoh M; Kataoka K; Wakabayashi M; Kitagawa Y
Jpn J Clin Oncol; 2017 Jun; 47(6):480-486. PubMed ID: 28334858
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
Kitasaki N; Hamai Y; Emi M; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Okada M
In Vivo; 2022; 36(6):2852-2860. PubMed ID: 36309376
[TBL] [Abstract][Full Text] [Related]
15. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.
Sugase T; Kanemura T; Takeoka T; Matsuura N; Masuike Y; Shinno N; Hara H; Kitakaze M; Kubo M; Mukai Y; Sueda T; Hasegawa S; Akita H; Nishimura J; Wada H; Yasui M; Omori T; Miyata H
Anticancer Res; 2024 Jan; 44(1):185-193. PubMed ID: 38159967
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer.
Otowa Y; Nakamura T; Yamamoto M; Kanaji S; Matsuda Y; Matsuda T; Oshikiri T; Sumi Y; Suzuki S; Kakeji Y
Dis Esophagus; 2017 Dec; 30(12):1-5. PubMed ID: 28881893
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Kanda M; Koike M; Iwata N; Shimizu D; Tanaka C; Hattori N; Hayashi M; Yamada S; Omae K; Nakayama G; Kodera Y
Oncologist; 2020 Nov; 25(11):e1650-e1654. PubMed ID: 32557987
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
20. Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery.
Oguma J; Ishiyama K; Kurita D; Kanematsu K; Fujii Y; Kubo K; Yamamoto S; Honma Y; Kato K; Daiko H
Esophagus; 2022 Apr; 19(2):214-223. PubMed ID: 34757482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
